Alexander KarpAlexander Karp earned $1B in 2024

In 2024, Lawrence Klein earned $203.29K in total compensation at Oruka Therapeutics, Inc., primarily from $203.29K salary. Most recently acquired 24,500 shares in Oct 2022. Currently holds stock worth $2.91M. 1+ years at the helm of Oruka Therapeutics, Inc..

Compensation History

Annual executive compensation data for Lawrence Klein, including salary, bonuses, and stock awards.

Year

2024

Total Compensation

$203.29K

Salary

$203.29K

Bonus

$0.00

Other

$0.00

Salary

$203.29K

Board Justification

In December 2024, our Compensation Committee adopted a compensation philosophy to frame future compensation decisions for the Company. Under this philosophy, compensation positioning is used to attract and retain key employees for the Company’s continued success and growth. While market data is helpful to the Compensation Committee in setting the compensation framework and guiding decisions, other factors such as Company strategy, stockholder feedback, tenure, performance and criticality are also considered. The compensation philosophy serves as the foundation to reinforce the Company’s business strategy and desired culture, while balancing internal and external alignment.

Bonus

$0.00

Board Justification

N/A

Other Compensation

$0.00

Board Justification

N/A

Restricted Stock

$0.000 N/A

Board Justification

N/A

Performance Metrics

Pre-Merger Oruka established the corporate goals and targets for the 2024 bonus program, which were heavily weighted towards the preclinical development of ORKA-001 and ORKA-002, progress towards the commencement of their respective Phase 1 clinical studies and regulatory progress. In addition, the corporate goals included measures designed to ensure adequate funding for the Company.

O

Lawrence Klein

Founder and CEO of Oruka Therapeutics, Inc.

Education

Ph.D. in biophysics from Stanford University

CEO of Oruka Therapeutics, Inc. for

1 year 3 months (Aug 2024 - Present)

Previous Experience

Partner at Versant Venture Management, LLC; Chief Operating Officer at CRISPR Therapeutics AG

Holdings

Track Lawrence Klein's stock holdings and portfolio value over time.

Total Stock Sold

$25.30M

CRSP

$25.30M

240,000 CRSP shares

What if they kept their stock?

If Lawrence Klein didn't sell their stock, today they would have:
Extra CRSP240,000 shares worth $13.69M.
This is -45.89% and $11.61M less than what they got when they sold the stock.

Insider Trading

Lawrence Klein's recent stock transactions, purchases, and sales filed with the SEC.

JSPR

24,500 shares

JSPR

Oct 12, 2022

Received

CRSP

$12.76M

CRSP at $127.59/share

Mar 23, 2021

Sale

CRSP

$5.38M

CRSP at $215.28/share

Jan 15, 2021

Sale

CRSP

$5.31M

CRSP at $75.82/share

Jun 24, 2020

Sale

CRSP

$1.52M

CRSP at $60.73/share

May 11, 2020

Sale

CRSP

$1.00M

CRSP at $50.02/share

Jul 10, 2019

Sale

CRSP

$597.40K

CRSP at $29.87/share

Jan 2, 2019

Received

Rivals

Compare Lawrence Klein with competitor CEOs and industry peers.